The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study
Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY
Progress in neuro-psychopharmacology & biological psychiatry · 265 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute for Health and Care Research
- Gobierno
- National Science Council
- Universidad u hospital
- Taipei Hospital
- Gobierno
- National Institute for Health Research (NIHR)
- Subvenciones
- National Institute for Health and Care Research (93-TD-1095)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2008-05-26 · Prog Neuropsychopharmacol Biol Psychiatry · vol. 32 · número 6 · págs. 1538–1544
- Editorial
- Elsevier BV
- Citado
- 406 citas · más que el 100% de estudios similares · 16.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 43 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Dementia and Cognitive Impairment Research · Alzheimer's disease research and treatments
- Palabras clave
- omega-3 polyunsaturated fatty acids, Alzheimer's disease, mild cognitive impairment, monotherapy, eicosapentaenoic acid, red blood cell membrane fatty acids, cognitive function, treatment tolerability, CIBIC-Plus, ADAS-Cog
- MeSH
- erythrocyte membrane, humans, alzheimer disease, fatty acids, omega-3, eicosapentaenoic acid, fatty acids, unsaturated, treatment outcome, double-blind method, cognition disorders, psychiatric status rating scales, neuropsychological tests, aged, aged, 80 and over, female, male
8 autores
- Chih-Chiang Chiu🇬🇧🇹🇼King's College London; Taipei Municipal YangMing Hospital; Taipei City Hospital; Taipei Medical University
- Kuan‐Pin Su🇹🇼China Medical University; China Medical University Hospital
- Tsung‐Chi Cheng🇹🇼National Chengchi University
- Hsing‐Cheng Liu🇹🇼Taipei Municipal YangMing Hospital; Taipei City Hospital
- Ching-Jui Chang🇹🇼Cathay General Hospital
- Michael E. Dewey🇬🇧King's College London
- Robert Stewart🇬🇧King's College London
- Shih‐Yi Huang🇹🇼 · autor de correspondenciaTaipei Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer's disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8 g/day or placebo (olive oil). The data of 35 (76%) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p=0.008). There was no significant difference in the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p=0.03), which was not observed in those with Alzheimer's disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p=0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer's disease and mild cognitive impairment.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.